文献速递艾滋病与性传播感染病毒性肝炎

HIV/HCV共感染者DAA治愈后肝硬度变化:NNRTI方案影响

Liver stiffness change with HCV cure in HIV-infected patients on non-nucleoside analogues.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

分析显示,含NNRTI方案者肝硬度下降百分比高于PI或INI方案者(35.2% vs 29.5%,P=0.018),多因素分析中NNRTI使用与肝硬度下降更多独立相关。

要点

  • HIV/HCV共感染者DAA治愈后,含NNRTI方案肝硬度下降幅度更大。
  • NNRTI组肝硬度下降中位百分比35.2%,非NNRTI组29.5%。
  • 多因素分析支持NNRTI方案与肝硬度下降独立相关。

核心结论

  • 在HIV/HCV共感染接受DAA治疗的患者中,含NNRTI加2个NRTI的方案与其他ART方案相比,与肝硬度下降更多相关。

主要发现

  • 基线肝硬度中位数NNRTI组16.7 kPa,非NNRTI组17.3 kPa(P=0.278)。
  • 从基线至SVR肝硬度下降中位百分比:NNRTI组35.2%,PI或INI组29.5%(P=0.018)。
  • 多因素分析校正后,NNRTI方案与肝硬度下降更多相关[β=11.088(95%CI=1.67-20.51);P=0.021]。

临床怎么用

  • 对于HIV/HCV共感染且基线肝硬度较高的患者,选择含NNRTI的ART方案可能有助于DAA治愈后肝硬度下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liver stiffness (LS) at sustained viral response (SVR) is strongly associated with a lower incidence of subsequent hepatic events. HIV NNRTIs may have a beneficial impact on fibrogenesis. OBJECTIVES: Our aim was to analyse the influence of NNRTI-based therapy on the change in LS from starting direct-acting antiviral (DAA) therapy to achieving SVR in HIV/HCV-coinfected patients. METHODS: Three hundred and thirteen HIV/HCV-coinfected patients who fulfilled the following criteria were included: (i) had achieved SVR with an IFN-free, DAA-including regimen; (ii) LS ≥9.5 kPa before therapy; (iii) LS measurement available at SVR; (iv) seronegative for HBsAg; and (v) ART containing 2 NRTIs plus either 1 NNRTI or 1 integrase inhibitor (INI) or 1-2 NRTIs plus 1 PI. LS changes were assessed. RESULTS: Seventy-four patients received NNRTI-based combinations [53 (71.6%) rilpivirine and 16 (21.6%) efavirenz] and 239 patients received other regimens. At baseline, the median (IQR) LS was 16.7 kPa (11.8-25.6) in the NNRTI group and 17.3 kPa (11.9-27.4) in the non-NNRTI group (P = 0.278). The median (IQR) percentage of LS decrease from baseline to SVR was 35.2% (18.2%-52.3%) for NNRTI-based therapy and 29.5% (10%-45.9%) for PI- or INI-based therapy (P = 0.018). In multivariate analysis, adjusted for sex, age, HCV genotype, NRTI backbone and propensity score for HIV therapy, NNRTI-based regimen use was associated with a higher LS decrease [β = 11.088 (95% CI = 1.67-20.51); P = 0.021]. CONCLUSIONS: Treatment with NNRTI plus 2 NRTI combinations is associated with a higher LS decline than other ART combinations in HIV/HCV-coinfected patients receiving DAA-based therapy.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Gonzalez-Serna A, Corma-Gomez A, Tellez F, et al. Liver stiffness change with HCV cure in HIV-infected patients on non-nucleoside analogues. J Antimicrob Chemother. 2021. PMID: 34021755. doi:10.1093/jac/dkab157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。